RNAi Therapeutics Market

Market Statistics:

• Global RNAi Therapeutics Market was worth USD 779.65 million in 2021
• Is expected to reach a valuation of USD 1501.04 million by 2028
• Registering a CAGR of 9.81% over 2022-2028

Worldwide RNAi Therapeutics Market has been assessed on the basis of various market-based aspects. In this report, 2021 has been taken as the base year. Further, the forecast period of 2022-2029 has been considered for the overall market analysis.

Scope:

RNA interference is a biological process in which target mRNA molecules are neutralized and RNA molecules are observed to inhibit gene expression or translation. Furthermore, RNA interference (RNAi) is a collection of small RNA-directed mechanisms that result in sequential-specific inhibition of genetic expression. The idea that RNAi could bring a new class of treatment immediately caught the attention of many investigators. The applied RNAi therapeutic field has been experimented with very quickly from the laboratory to the bedside. The RNAi approach is widely used for drug development and clinical trials I and II are underway in several phases. Furthermore, RNAi therapy makes it possible to calm specific and highly effective genes. RNAi therapies provide an opportunity to alter the expression of genes, and as such, it is considered an effective therapy for targeting rib nucleotide seeds (RNA). It is widely used in oncology, cardiovascular diseases, respiratory disorders, kidney diseases, neurodegenerative disorders, genetic disorders, infectious diseases, and others. Additionally, the concept of RNA interference (RNAi) was introduced in the 1980s. It is based on the selective silence of a specific number of mRNAs, which in turn, inhibits the ability of disease-proteins to cause disease. This phenomenon first appeared in petunia flowers and was later studied in C elegans. Notably, this discovery was awarded the Nobel Prize in 2006. Although the technique was discovered less than two decades ago, RNAi has had a significant impact in the pharmaceutical sector, and currently, there is a robust pipeline of drug candidates based on this principle.

High investment and strict regulations are some of the major restrictions on this market. The distribution of RNAi drugs for tissue specification is one of the major challenges facing the market. The high costs associated with research are controlling the market and challenging the growth of the global RNAI therapeutic market. Inadequate infrastructure of health services in developing countries includes factors in market development, high risk of failure, lack of skilled professionals in drug control laboratories and lack of RNAI therapeutic appropriate distribution network. Accurate distribution of RNA molecules is a difficult challenge for companies involved in the global RNAI therapeutic market.

COVID-19 Impact:

Coronavirus is a rapidly emerging disease worldwide with devastating consequences. COVID-19 is affecting important markets around the world. (Epidemic) drug, drug industry, supplies chain operations all over the country (or across the continent) are being prohibited prominently. Key players in the RNAi drug delivery market focus on developing vaccines with the help of gene slicing technology, which is expected to drive growth in the RNAi drug distribution market. The natural RNAi process can be involved in developing the best quality treatments to overcome diversity. In addition, this procedure enables specific binding and calming of therapeutic targets using short interfering RNA (CRNA). Furthermore, as COVID-19 is expected to continue worldwide, a fundamental increase is seen in the demand for RNAi drug delivery technology which drives the growth during the assessment period.

Key Players:

• Alnylam Pharmaceuticals Inc.
• Sanofi
• Olix Pharmaceuticals Inc.
• Glaxosmithkline Plc.
• Benitec Biopharma
• Arbutus Biopharma Corporation
• Silence Therapeutics
• Rexahn Pharmaceuticals Inc.
• Arrowhead Pharmaceuticals Inc
• Quark
• Entos Pharmaceuticals Inc.
• Sylentis
• Genevant Sciences
• Sirnaomics Inc.
• others

Segmentation:

By Molecule Type

• Small Interfering RNAs (siRNA)
• MicroRNA (miRNA)

The Small Interfering RNAs (siRNA) segment is expected to expand considerably over 2022-2030. This is attributable to the rise number of research partnerships and the growing use of these molecules  to develop drugs for the treatment  target diseases.

By Application

• Oncology
• Cardiovascular
• Respiratory Disorders
• Renal Diseases
• Genetic Disorders
• Neurodegenerative Disorders
• Infectious Diseases
• Others

The oncology segment is reckoned to garner substantial returns over 2022-2030 due to the growing pervasiveness of cancer due to factors such as age, genetics, and rising pollution levels, among others. The efficacy of RNAi therapies to treat various cancer forms is further driving the segmental growth.

By Route of Administration

• Pulmonary Delivery
• Intravenous Injections
• Intradermal Injections
• Intraperitoneal Injections
• Others

The intravenous injections segment is poised to grow exponentially over the estimated timeframe owing to the increasing number of associated products launched by prominent players operating in the market.

By End User

• Research and Academic Laboratories
• Hospitals
• Diagnostic Laboratories

Geographical Landscape

The major regions characterizing the geographical terrain of this industry are-

• North America
• Middle East & Africa
• Europe
• Asia Pacific
• Latin America

Major Growth Drivers:

• Increasing incidence of chronic and infectious ailments
• Booming medical research sector
• Technological evolution

Key Trends:

Increasing collaborative activities are boosting the growth of RNAi Therapeutics Industry

The increasing collaborative activities between drug distribution companies and contract research organizations (CROs) are contributing to the growth of the antisense and RNAI therapeutic market. In January 2016, Ionis Pharmaceuticals (previously Isis Pharmaceuticals) initiated a Phase-I study of ISIS-HBV-L Rx in collaboration with GSK Pharmaceuticals. This acquisition aims to the treatment of Hepatitis B viral infection. And also one more collaboration by Ionis pharmaceuticals with Akcea Therapeutics has led to the approval of the world’s first antisense-based molecule “Tegsdi” by the FDA and the European Commission in 2018. Also, cancer deaths have been on the rise in recent years. Such as, according to the World Health Organization, cancer is the second leading cause of death globally and is responsible for an estimated 9.6 million deaths in 2018. Globally, about 1 in 6 deaths is due to cancer. Because of this death ratio increasing awareness in citizens and increase in the adoption of RNAi therapeutics in the market. Moreover, Advances in drug delivery technology have been a major driver of growth in the RNAI Therapeutics market. These treatments are used in the treatment of rare and chronic diseases. The increase in research and development work to treat these diseases plays an important role in the growth of the RNAI therapeutic market. Additionally, Successful clinical trials of pipeline products should expand the market. Discovery RNAI therapy pipeline products can be very effective in the treatment of rare diseases such as Huntington’s disease. These positive clinical trials of therapeutic drugs are influencing the growth of the market.

Increasing R&D activities in the field of nanotechnology is augmenting the industry outlook

The increased focus on research and development work by public institutions on nanotechnology is expected to create more growth opportunities for the market in the forecast period to meet the ever-increasing demand for RNAI therapeutics. The growing economies of countries such as the UK, Canada and highly populated China and India, where healthcare is booming, are creating huge opportunities for stakeholders and those involved in the global RNAi therapeutic market.

Expounding the geographical landscape of this industry:

North America- This region is anticipated to dominate the Global RNAi Therapeutic Market. The U.S. has a several RNAi therapies that are in the developmental pipeline. Many biotechnology companies have invested heavily in RNAi therapeutic development. Many pharmaceutical developers have entered into cooperation agreements or licensing agreements with a number of small companies in an effort to capitalize on the expected growth in revenue during the forecast period of this market. For example, AstraZeneca's deal with Ionis Pharmaceuticals is a major deal, investing heavily in RNA-interference technology. Also in September 2018, Delos Capital developed MRNA-based drugs for chemotherapy-resistant cancer. Curamir Therapeutics received initial financial support. With the help of these new companies, and acquisitions as well as new inventions, North America is dominating the market.

Asia Pacific- This region is projected to showcase lucrative growth rates over the forecast duration. The rising continuous R&D activity in RNAi therapies has revealed its benefits associated with chronic disorders such as genetic conditions, kidney disorders, neurodegenerative conditions, and oncology. The effectiveness of RNAi therapy results in an investment in the development of new drugs. For example, in June 2020, OliX Pharmaceuticals entered into an agreement with LGC Biosarch Technology to accelerate the production of asymmetric siRNA for the treatment of sub-retinal fibrosis and wet macular degeneration. Also, NantVentures has publicly invested in Australia-based Biotech Benitec Biopharma. Furthermore, Benitec and Nan ventures, with the help of Nantworks, plan to launch an oncology-focused R&D collaboration with Benitec-led clinical development and clinical evaluation. Such investments allow biotech and pharma companies to not only bring new products to market but also increase the number of approved products. Market players are investing in research and development of new drugs, therapies and technologies. This growing investment in RNAi therapies has spurred market growth in Asia Pacific region.

Middle East & Africa- This region is reckoned to garner significant returns in the ensuing years. The growing prevalence of chronic ailments, increasing health expenditure, rise in the geriatric population base, and rapid evolution in the medical research dynamics is contributing to the overall market development. Alongside, growing health cognizance among the masses, rapidly developing healthcare infrastructure, surging R&D investments, emergence of potential players, and favourable medical reimbursement scenario in this region is further bolstering the overall industry expansion.

Major Developments:

Alnylam has got Approval in Brazil of ONPATTRO for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy

On February 26, 2020, Alnylam Pharmaceuticals, Inc. RNAi Therapeutics, a leading company has announced that the Brazilian Health Regulatory Agency (ANVISA) has approved ONPATTRO for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis in adults with stage 1 or stage 2 polyneuropathy. hATTR amyloidosis is a rare, progressive condition that is considered endemic in Brazil and affects more than 5,000 people. Based on the Nobel Prize-winning science, ONPATTRO is the first approved RNAi therapeutic in Latin America, as well as the first aluminum product to be marketed and marketed in the region. With the approval of ONPATTRO in Brazil, there is a need for a new treatment option for people with hATTR amyloidosis to stop the progression of this debilitating and life-threatening disease. For this purpose, this drug is recognized in Brazil.

Report Analysis	Details
Historical data	2016 - 2021
Forecast Period	2022 - 2029
Market Size in 2021:	779.65 Million
Base year considered	2021
Forecast Period CAGR %:	9.81%
Market Size Expected in 2028:	1501.04 Million
Tables, Charts & Figures:	175
Pages	300
Key Players/Companies	Alnylam Pharmaceuticals, Inc., Sanofi, Olix Pharmaceuticals, Inc., Glaxosmithkline Plc., Benitec Biopharma, Arbutus Biopharma Corporation, Silence Therapeutics, Rexahn Pharmaceuticals, Inc., Arrowhead Pharmaceuticals, Inc, Quark, Entos Pharmaceuticals Inc., Sylentis, Genevant Sciences, Sirnaomics Inc., others.
Segments Covered	By Molecule Type, By Application, By Route of Administration, By End User
Regional Analysis	North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa